SEC Info - Allogene Therapeutics, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Allogene Therapeutics, Inc.
CA
SEC # 1737287

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

3/14/24	S-3	1	About This Prospectus	3
11/2/23	424B5	1	About This Prospectus Supplement	1
4/23/24	DEF 14A	1	Advisory Vote on Executive Compensation	1
		1	Agreements with our Named Executive Officers	1
		1	Audit Committee	1
		1	Board Leadership Structure	1
		1	Board Qualifications	1
3/14/24	10-K	1	Business	2
		1	Certain Relationships and Related Transactions, and Director Independence	2
		1	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	2
4/23/24	DEF 14A	1	Clawback Policy	1
		1	Code of Ethics	1
		1	Compensation Committee	1
		1	Compensation Highlights for 2023	1
11/2/23	10-Q	1	Condensed Consolidated Balance Sheets	3
		1	Condensed Consolidated Statements of Cash Flows	3
		1	Condensed Consolidated Statements of Operations and Comprehensive Loss	3
		1	Condensed Consolidated Statements of Stockholders' Equity	3
3/14/24	10-K	1	Consolidated Balance Sheets	2
		1	Consolidated Statements of Cash Flows	2
		1	Consolidated Statements of Operations and Comprehensive Loss	2
		1	Consolidated Statements of Stockholders' Equity	2
		1	Controls and Procedures	5
4/23/24	DEF 14A	1	Corporate Highlights for 2023	1
3/14/24	10-K	1	Cybersecurity	1
11/2/23	10-Q	1	Defaults Upon Senior Securities	3
4/23/24	DEF 14A	1	Delinquent Section 16(A) Reports	1
3/14/24	S-3	1	Description of Capital Stock	3
		1	Description of Debt Securities	3
		1	Description of Warrants	3
		1	Dilution	2
4/23/24	DEF 14A	1	Directors Continuing in Office Until the 2025 Annual Meeting	1
		1	Directors Continuing in Office Until the 2026 Annual Meeting	1
3/14/24	10-K	1	Directors, Executive Officers and Corporate Governance	2
		1	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	2
4/23/24	DEF 14A	1	Discussion of Named Executive Officer Compensation	1
		1	Election of Directors	1
		1	Environmental, Social & Governance (ESG) Practices	1
		1	Executive Chair Compensation	1
		1	Executive Compensation	3
		1	Executive Compensation Governance Practices	1
		1	Executive Compensation Philosophy and Overview	1
		1	Executive Compensation Program and Compensation Decisions for the Named Executive Officers	1
		1	Executive Officers	1
11/2/23	10-Q	1	Exhibits	3
3/14/24	10-K	1	Exhibits, Financial Statement Schedules	2
3/14/24	S-3	1	Experts	3
11/2/23	10-Q	1	Financial Information	3
		1	Financial Statements	3
3/14/24	10-K	1	Financial Statements and Supplementary Data	2
3/14/24	10-K/A	1	Form 10-K	1
3/14/24	10-K	1	Form 10-K Summary	1
4/23/24	DEF 14A	1	General	1
		1	Health and Welfare Benefits	1
		1	Householding of Proxy Materials	1
3/14/24	S-3	1	Incorporation of Certain Information by Reference	3
4/23/24	DEF 14A	1	Independence of The Board of Directors	1
		1	Information Regarding Committees of the Board of Directors	1
		1	Information Regarding the Board of Directors and Corporate Governance	1
		1	International and Business Development Oversight Committee	1
3/14/24	10-K	1	Item 1	5
		1	Item 10	2
		1	Item 11	2
		1	Item 12	2
		1	Item 13	2
		1	Item 14	2
		1	Item 16	2
		1	Item 1A	5
		1	Item 1B	2
		1	Item 2	5
		1	Item 3	5
		1	Item 4	5
		1	Item 5	5
		1	Item 6	5
		1	Item 7	2
		1	Item 7A	2
		1	Item 8	2
		1	Item 9	2
		1	Item 9A	2
		1	Item 9B	2
3/14/24	S-3	1	Legal Matters	3
		1	Legal Ownership of Securities	3
3/14/24	10-K	1	Legal Proceedings	5
		1	Management's Discussion and Analysis of Financial Condition and Results of Operations	5
		1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	2
4/23/24	DEF 14A	1	Meetings of The Board of Directors	1
3/14/24	10-K	1	Mine Safety Disclosures	5
4/23/24	DEF 14A	1	Narrative to Summary Compensation Table	1
		1	Nominating and Corporate Governance Committee	1
		1	Nominees for Election at the Annual Meeting	1
		1	Non-Employee Director Compensation Policy	1
11/2/23	10-Q	1	Notes to Condensed Consolidated Financial Statements	3
3/14/24	10-K	1	Notes to Consolidated Financial Statements	2
		1	Other Information	5
4/23/24	DEF 14A	1	Other Matters	1
		1	Our Board of Directors	1
		1	Overview	1
3/14/24	10-K	1	Part I	5
		1	Part Ii	5
		1	Part Iii	2
		1	Part Iv	2
4/23/24	DEF 14A	1	Pay Versus Performance	1
		1	Peer Group and Market Compensation Data	1
		1	Perquisites and Other Personal Benefits	1
3/14/24	S-3	1	Plan of Distribution	3
4/23/24	DEF 14A	1	Potential Payments and Benefits Upon Termination or Change in Control	1
3/14/24	S-3	1	Power of Attorney (included on signature page)	1
3/14/24	S-8	1	Power of Attorney. Reference is made to the signature page hereto	2
3/14/24	10-K	1	Principal Accounting Fees and Services	2
4/23/24	DEF 14A	1	Process for Setting Executive Compensation	1
		1	Prohibition on Hedging, Pledging, and Speculative Trading	1
3/14/24	10-K	1	Properties	2
4/23/24	DEF 14A	1	Proposal 1 -- Election of Directors	1
		1	Proposal 2 -- Advisory Vote on Executive Compensation	1
		1	Proposal 3 -- Ratification of Selection of Independent Registered Public Accounting Firm	1
3/14/24	S-3	1	Prospectus Summary	2
11/2/23	424B5	1	Prospectus Supplement Summary	1
3/14/24	10-K	1	Quantitative and Qualitative Disclosures About Market Risk	5
4/23/24	DEF 14A	1	Questions and Answers about These Proxy Materials and Voting	1
		1	Ratification of Selection of Independent Registered Public Accounting Firm	1
3/14/24	10-K	1	Report of Independent Registered Public Accounting Firm	2
4/23/24	DEF 14A	1	Report of the Audit Committee of the Board of Directors	1
		1	Research and Development Committee	1
3/14/24	10-K	1	Reserved	2
4/23/24	DEF 14A	1	Risk Assessment Concerning Compensation Practices and Policies	1
3/14/24	S-3	1	Risk Factors	8
4/23/24	DEF 14A	1	Role of Independent Compensation Consultant	1
		1	Role of Management	1
		1	Role of the Board in Risk Oversight	1
		1	Role of the Compensation Committee	1
		1	Say on Pay	1
		1	Section 401(k) Plan	1
		1	Securities Authorized for Issuance under Equity Compensation Plans	1
3/14/24	10-K	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2
4/23/24	DEF 14A	1	Security Ownership or Certain Beneficial Ownership and Management	1
11/2/23	10-Q	1	Signatures	3
3/14/24	S-3	1	Special Note Regarding Forward-Looking Statements	3
4/23/24	DEF 14A	1	Stock Ownership Guidelines	1
		1	Stockholder Communications with The Board of Directors	1
3/14/24	S-3	1	Summary	4
		1	Table of Contents	8
4/23/24	DEF 14A	1	Transactions with Related Persons	1
11/2/23	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	3
3/14/24	10-K	1	Unresolved Staff Comments	2
3/14/24	S-3	1	Use of Proceeds	3
		1	Where You Can Find More Information	3
3/14/24	10-K	1	100	2
		1	101	1
		1	102	1
		1	103	1
		1	104	1
		1	105	1
		1	106	1
3/14/24	10-K/A	1	129	1
		1	132	1
		1	133	1
		1	136	1
		1	137	1
		1	139	1
3/14/24	10-K	1	141	1
		1	142	1
		1	143	1
		1	146	1
		1	147	1
		1	149	1
4/23/24	DEF 14A	1	2023 Annual Base Salary	1
		1	2023 Annual Performance-Based Cash Incentive	1
		1	2023 Director Compensation table	1
		1	2023 Long-Term Incentive Compensation	1
		1	2023 Outstanding Equity Awards at Fiscal Year-End Table	1
		1	2023 Summary Compensation Table	1

↑Top

Allogene Therapeutics, Inc. CA SEC # 1737287

334 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Allogene Therapeutics, Inc.
CA
SEC # 1737287

334 Topics
within the